MYMohammad Yaghoubzad-Maleki

Mohammad Yaghoubzad-Maleki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohammad Yaghoubzad-Maleki has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The effects of novel point mutations in the BRCA1 protein structure of breast cancer patients with breast or ovarian familial cancer history: an in-silico study

    by Mohsen Nabi-Afjadi, Mohammad Yaghoubzad Maleki, Fatemeh Sadat Seyedi Asl, Mohammad Yazdanpour, Fatemehsadat Ataei Kachouei, Payam Baziyar


  • Catharanthine, an anticancer vinca alkaloid: an in silico and in vitro analysis of the autophagic system as the major mechanism of cell death in liver HepG2 cells

    by Farnoosh Gholami, Bagher Seyedalipour, Nafiseh Heidari-Kalvani, Mohsen Nabi-Afjadi, Mohammad Yaghoubzad-Maleki, Zeinab Fathi, Iraj Alipourfard, Fereshte Barjesteh, Elham Bahreini

    Catharanthine, a component of the anticancer drug vinblastine along with vindoline, disrupts the cell cycle by interfering with mitotic spindle formation. Apart from their antioxidant properties, vinca alkaloids like catharanthine inhibit phosphodiesterase activity and elevate intracellular cAMP levels. The aim of this study was to investigate how catharantine affects apoptosis and autophagy. This study conducted experiments on HepG2 liver carcinoma cells with varying doses of catharanthine to evaluate cell death rates and viability and determine the IC50 concentration via MTT assays. The apoptotic and autophagic effects of catharanthine were assessed using flow cytometry with annexin V and PI staining, while the expression of autophagy-related genes was analyzed through quantitative PCR. Additionally, molecular docking and molecular dynamics simulations were employed to further investigate catharanthine’s impact on autophagy mechanisms. The study showed that catharanthine reduced oxidative stress and triggered apoptosis in HepG2 cells in a dose-dependent manner. Catharanthine also upregulated the expression of autophagy-related genes like LC3, Beclin1, and ULK1. Notably, catharanthine increased sirtuin-1 levels, a known autophagy inducer, while decreasing Akt expression compared to untreated cells. Molecular docking results indicated rapamycin had a stronger binding affinity with FRB (−10.7 KJ/mol−1) than catharanthine (−7.3 KJ/mol−1). Additionally, molecular dynamics simulations revealed that catharanthine interacted effectively with the FRB domain of mTOR, displaying stability and a strong binding affinity, although not as potent as rapamycin. In summary, besides its cytotoxic and pro-apoptotic effects, catharanthine activates autophagy signaling pathways and induces autophagic necrosis by inhibiting mTOR.


  • Insights on the interaction mechanism of sesquiterpene coumarin (7-geranyloxycoumarin) to double-strand DNA by multispectral techniques and molecular docking

    by Bahar Dehghan, Gholamreza Dehghan, Masoomeh Shaghaghi, Samaneh Rashtbari, Mohammad Yaghoubzad-Maleki, Mehrdad Iranshahi


  • Open Access

    Immunoinformatics Approach to Design a Chimeric CD70‐Peptide Vaccine against Renal Cell Carcinoma

    by Haideh Namdari, Farhad Rezaei, Fatemeh Heidarnejad, Mohammad Yaghoubzad-Maleki, Maryam Karamigolbaghi

    Renal cell carcinoma (RCC) accounts for the majority of cancer‐related deaths worldwide. Overexpression of CD70 has been linked to advanced stages of RCC. Therefore, this study aims to develop a multiepitope vaccine targeting the overexpressed CD70 using immunoinformatics techniques. In this investigation, in silico multiepitope vaccines were constructed by linking specific CD70 protein epitopes for helper T lymphocytes and CD8+ T lymphocytes. To enhance immunogenicity, sequences of cell‐penetrating peptide (CPP), penetratin (pAntp), along with the entire sequence of tumor necrosis factor‐α (TNF‐α), were attached to the N‐terminal and C‐terminal of the CD70 epitopes. Computational assessments were performed on these chimeric vaccines for antigenicity, allergenicity, peptide toxicity, population coverage, and physicochemical properties. Furthermore, refined 3D constructs were subjected to a range of analyses, encompassing structural B‐cell epitope prediction and molecular docking. The chosen vaccine construct underwent diverse assessments such as molecular dynamics simulation, immune response simulation, and in silico cloning. All vaccines comprised antigenic, nontoxic, and nonallergenic epitopes, ensuring extensive global population coverage. The vaccine constructs demonstrated favorable physicochemical characteristics. The binding affinity of chimeric vaccines to the TNF receptor remained relatively stable, influenced by the alignment of vaccine components. Molecular docking and dynamics analyses predicted stable interactions between CD70‐CPP‐TNF and the TNF receptor, indicating potential efficacy. In silico codon optimization and cloning of the vaccine nucleic acid sequence were accomplished using the pET28a plasmid. Furthermore, this vaccine displayed the capacity to modulate humoral and cellular immune responses. Overall, the results suggest therapeutic potential for the chimeric CD70‐CPP‐TNF vaccine against RCC. However, validation through in vitro and in vivo experiments is necessary. This trial is registered with NCT04696731 and NCT04046445.


  • A Review of the Potential Role of CoQ10 in the Treatment of Hepatocellular Carcinoma

    by Mahsa Liaghat, Mohammad Yaghoubzad-Maleki, Mohsen Nabi-Afjadi, Zeinab Fathi, Hamidreza Zalpoor, Nafiseh Heidari, Elham Bahreini

    The coenzyme ubiquinone-10 (CoQ10) is not only an important part of the electron transport chain of the mitochondrial inner membrane but also has complex biological functions beyond mitochondrial respiration. It is a natural nutrient that is not only produced by the body but is also found in foods, such as meat, eggs, fish, and vegetable oils. Because some types of cancer reduce CoQ10 blood levels, the use of CoQ10 supplements is recommended for the treatment of cancer patients. The anti-cancer effects of CoQ10 supplementation have been reported in several cancers, including colon and breast cancer. CoQ10 scavenges free radicals to reduce oxidative stress and minimize tissue damage. CoQ10 protects the body from damage caused by chemotherapy drugs by reducing the production of inflammatory cytokines and other inflammatory factors. Recent studies suggest that CoQ10 may be a supplement to pharmacotherapy for hepatocellular carcinoma. This article examines the effects of CoQ10 in hepatocellular carcinoma.